Flyte Device for Improving Urinary Incontinence Among Endometrial and Cervical Cancer Survivors Who Have Undergone Radiation Therapy

Inclusion Criteria: * Female patients who have received conventionally fractioned adjuvant or primary pelvic radiation therapy for endometrial or cervical cancer ≥ 3 months prior to registration * Age ≥ 21 years at enrollment * English speaking * Demonstrates understanding of the study protocol and has signed the Informed Consent Form (ICF) * Has a clinical diagnosis of urinary incontinence (stress urinary incontinence \[SUI\], urge urinary incontinence \[UUI\], mixed) or overactive bladder (OAB) * Ability to contract the pelvic floor muscles (PFMs) without pain * Ability to tolerate size 6 vaginal dilator * Internet access * Access to an iOS or Android smartphone or tablet with capabilities to download and use the Flyte app * Willing and able to participate in follow-up Exclusion Criteria: * Participation in another clinical study which may interfere with study requirements * Currently receiving active cancer directed therapy (i.e., cytotoxic chemotherapy) in post hysterectomy patients * Completion of radiation therapy or surgery within 3 months of enrollment * Life expectancy is less than six months in the opinion of the investigator * Inability to tolerate insertion of the intravaginal wand. This will be recorded to support the usability of Flyte secondary endpoint * Suspected vesicovaginal or colovaginal fistula * Physical limitations that impede the patient's ability to participate (e.g., ability to grasp the wand and insert it and ability to turn on the Flyte control…